Akineton

Name: Akineton

Descriptions

Biperiden is used alone or together with other medicines (e.g., levodopa) to treat Parkinson's disease. By improving muscle control and reducing stiffness, this medicine allows more normal movements of the body as the disease symptoms are reduced.

Biperiden is also used to control severe muscle reactions and other side effects from certain medicines that are used to treat severe nausea or nervous, mental, or emotional conditions (e.g., chlorpromazine [Thorazine®], perphenazine [Trilafon®], prochlorperazine [Compazine®], promethazine [Phenergan®], thioridazine [Mellaril®]).

This medicine is available only with your doctor's prescription.

This product is available in the following dosage forms:

  • Tablet

Patient information

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

Interactions for Akineton

Specific Drugs

Drug

Interaction

Comments

Alcohol

Possible additive CNS effectsa

Avoid concomitant usea

Anticholinergic agents

Increased risk of adverse anticholinergic effectsa b

Actions

  • Exhibits atropine-like blocking action on parasympathetic-innervated peripheral structures, including smooth muscle.a

  • Competitively inhibits acetylcholine or other cholinergic stimuli at autonomic effectors innervated by postganglionic nerves.a c

  • Weak peripheral anticholinergic agent with antisecretory, antispasmodic, and mydriatic effects.b

  • Exhibits nicotinolytic effects.a b Nicotinolytic effects >6 times that of atropine.b

Advice to Patients

  • Potential for drug to impair mental alertness or physical coordination; use caution when driving or operating machinery until effects on individual are known.a

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as concomitant illnesses.a

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Indications and Usage for Akineton

  • As an adjunct in the therapy of all forms of parkinsonism (idiopathic, postencephalitic, arteriosclerotic)
  • Control of extrapyramidal disorders secondary to neuroleptic drug therapy (e.g., phenothiazines)

Warnings

Isolated instances of mental confusion, euphoria, agitation and disturbed behavior have been reported in susceptible patients. Also, the central anticholinergic syndrome can occur as an adverse reaction to properly prescribed anticholinergic medication, although it is more frequently due to overdosage. It may also result from concomitant administration of an anticholinergic agent and a drug that has secondary anticholinergic actions (see PRECAUTIONS - Drug Interactions and OVERDOSAGE sections). Caution should be observed in patients with manifest glaucoma, though no prohibitive rise in intraocular pressure has been noted following either oral or parenteral administration. Patients with prostatism, epilepsy or cardiac arrhythmia should be given this drug with caution.

Occasionally, drowsiness may occur, and patients who drive a car or operate any other potentially dangerous machinery should be warned of this possibility. As with other drugs action on the central nervous system, the consumption of alcohol should be avoided during Akineton therapy.

Adverse Reactions

Atropine-like side effects such as dry mouth; blurred vision; drowsiness; euphoria or disorientation; urinary retention; postural hypotension; constipation; agitation; disturbed behavior may been seen. A case of generalized choreic movements has been reported in a Parkinson's disease patient when biperiden was added to carbidopa/levodopa. A reduction in rapid eye movement (REM) sleep, characterized by increased REM latency and decreased percentage of REM sleep, has been reported. There usually are no significant changes in blood pressure or heart rate in patients who have been given the parenteral form of Akineton. Mild transient postural hypotension and bradycardia may occur. These side effects can be minimized or avoided by slow intravenous administration. No local tissue reactions have been reported following intramuscular injection. If gastric irritation occurs following oral administration, it can be avoided by administering the drug during or after meals.

The central anticholinergic syndrome can occur as an adverse reaction to properly prescribed anticholinergic medication. See OVERDOSAGE section for signs and symptoms of the central anticholinergic syndrome, and for treatment.

How is Akineton Supplied

Akineton (biperiden hydrochloride) Tablets, 2 mg each, white, embossed on one face with a triangle, bisected on the reverse and imprinted with the number "11."

Bottles of 100 – NDC # 49884-693-01

Storage

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in USP.

Akineton is a registered trademark of Knoll AG.

Manufactured for:

PAR PHARMACEUTICAL, INC.

Spring Valley , New York  10977

Manufactured by:

Abbott Laboratories

North Chicago, IL 60064, U.S.A.

Akineton 
biperiden hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-693
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
biperiden hydrochloride (biperiden) biperiden 2 mg
Inactive Ingredients
Ingredient Name Strength
lactose  
magnesium stearate  
corn syrup  
potato starch  
talc  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 9mm
Flavor Imprint Code 11
Contains     
Coating false Symbol true
Packaging
# Item Code Package Description
1 NDC:49884-693-01 100 TABLET (100 TABLET) in 1 BOTTLE
Labeler - Abbott Laboratories
Revised: 06/2006   Abbott Laboratories

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

(web3)